Puma Total Revenue vs Depreciation And Amortization Analysis

PBYI Stock

USD 3.00 0.10 3.45%

Puma Biotechnology financial indicator trend analysis is much more than just breaking down Puma Biotechnology prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Puma Biotechnology is a good investment. Please check the relationship between Puma Biotechnology Total Revenue and its Depreciation And Amortization accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

Total Revenue vs Depreciation And Amortization

Total Revenue vs Depreciation And Amortization Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Puma Biotechnology Total Revenue account and Depreciation And Amortization. At this time, the significance of the direction appears to have strong relationship.

The correlation between Puma Biotechnology's Total Revenue and Depreciation And Amortization is 0.79. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Puma Biotechnology, assuming nothing else is changed. The correlation between historical values of Puma Biotechnology's Total Revenue and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Puma Biotechnology are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Total Revenue i.e., Puma Biotechnology's Total Revenue and Depreciation And Amortization go up and down completely randomly.

Correlation Coefficient

0.79

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Revenue

Total revenue comprises all receipts Puma Biotechnology generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Most indicators from Puma Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's Issuance Of Capital Stock is increasing as compared to previous years. The Puma Biotechnology's current Enterprise Value Over EBITDA is estimated to increase to 5.42, while Selling General Administrative is projected to decrease to under 65.7 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	10.6M	8.9M	10.2M	9.1M
Interest Income	160K	813K	2.4M	1.5M

Reconciled Depreciation Interest Income

Puma Biotechnology fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Total Current Liabilities	Retained Earnings	Accounts Payable	Other Current Liab	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Inventory
Total Assets		0.17	0.17	0.51	0.47	-0.64	0.45	0.85	0.69	0.89	-0.64	0.74	-0.76	0.59	0.66	0.5	-0.11	0.56	0.64	0.54	0.46	-0.75	0.32	0.61	0.82	-0.02
Total Stockholder Equity	0.17		-0.78	0.38	0.4	-0.27	-0.48	-0.28	-0.6	0.56	-0.27	-0.45	0.39	0.23	-0.54	-0.43	0.93	-0.51	-0.59	0.67	0.59	0.39	0.59	-0.65	-0.29	0.14
Net Debt	0.17	-0.78		-0.56	-0.57	0.06	0.62	0.48	0.71	-0.18	0.06	0.61	-0.59	0.04	0.65	0.42	-0.8	0.58	0.7	-0.2	-0.25	-0.59	-0.04	0.74	0.5	-0.01
Cash	0.51	0.38	-0.56		0.97	-0.44	-0.07	0.33	0.14	0.59	-0.44	0.16	-0.25	0.24	0.11	0.18	0.21	0.06	0.09	0.1	0.1	-0.25	-0.24	0.12	0.31	-0.22
Cash And Short Term Investments	0.47	0.4	-0.57	0.97		-0.47	-0.09	0.28	0.09	0.56	-0.47	0.12	-0.2	0.22	0.05	0.16	0.23	0.01	0.05	0.1	0.09	-0.2	-0.25	0.06	0.27	-0.25
Common Stock Total Equity	-0.64	-0.27	0.06	-0.44	-0.47		0.16	-0.43	-0.32	-0.63	1.0	-0.4	0.39	-0.4	-0.35	-0.21	0.01	-0.26	-0.31	-0.36	-0.28	0.38	-0.2	-0.26	-0.4	-0.1
Common Stock Shares Outstanding	0.45	-0.48	0.62	-0.07	-0.09	0.16		0.77	0.72	0.12	0.16	0.72	-0.75	0.23	0.63	0.56	-0.51	0.58	0.77	0.05	-0.05	-0.74	-0.12	0.67	0.79	-0.11
Other Stockholder Equity	0.85	-0.28	0.48	0.33	0.28	-0.43	0.77		0.9	0.54	-0.43	0.91	-0.96	0.52	0.83	0.66	-0.5	0.75	0.91	0.22	0.14	-0.95	-0.04	0.83	0.99	-0.16
Total Liab	0.69	-0.6	0.71	0.14	0.09	-0.32	0.72	0.9		0.32	-0.32	0.94	-0.9	0.31	0.94	0.72	-0.78	0.84	0.95	-0.05	-0.06	-0.9	-0.17	0.98	0.89	-0.12
Total Current Assets	0.89	0.56	-0.18	0.59	0.56	-0.63	0.12	0.54	0.32		-0.63	0.39	-0.42	0.58	0.3	0.18	0.3	0.23	0.23	0.71	0.64	-0.42	0.55	0.26	0.52	0.06
Common Stock	-0.64	-0.27	0.06	-0.44	-0.47	1.0	0.16	-0.43	-0.32	-0.63		-0.4	0.39	-0.4	-0.35	-0.21	0.01	-0.26	-0.31	-0.36	-0.28	0.38	-0.2	-0.26	-0.4	-0.1
Total Current Liabilities	0.74	-0.45	0.61	0.16	0.12	-0.4	0.72	0.91	0.94	0.39	-0.4		-0.91	0.34	0.95	0.76	-0.68	0.86	0.95	0.08	-0.01	-0.9	-0.11	0.85	0.91	0.0
Retained Earnings	-0.76	0.39	-0.59	-0.25	-0.2	0.39	-0.75	-0.96	-0.9	-0.42	0.39	-0.91		-0.46	-0.86	-0.67	0.61	-0.77	-0.93	-0.11	0.03	1.0	0.15	-0.87	-0.97	0.17
Accounts Payable	0.59	0.23	0.04	0.24	0.22	-0.4	0.23	0.52	0.31	0.58	-0.4	0.34	-0.46		0.22	0.08	0.0	0.2	0.28	0.69	0.67	-0.47	0.4	0.28	0.48	0.1
Other Current Liab	0.66	-0.54	0.65	0.11	0.05	-0.35	0.63	0.83	0.94	0.3	-0.35	0.95	-0.86	0.22		0.7	-0.73	0.9	0.93	-0.04	-0.07	-0.86	-0.17	0.88	0.82	0.0
Other Liab	0.5	-0.43	0.42	0.18	0.16	-0.21	0.56	0.66	0.72	0.18	-0.21	0.76	-0.67	0.08	0.7		-0.58	0.72	0.78	-0.07	-0.15	-0.66	-0.27	0.66	0.66	-0.14
Net Tangible Assets	-0.11	0.93	-0.8	0.21	0.23	0.01	-0.51	-0.5	-0.78	0.3	0.01	-0.68	0.61	0.0	-0.73	-0.58		-0.66	-0.77	0.51	0.48	0.61	0.52	-0.8	-0.51	0.15
Property Plant And Equipment Net	0.56	-0.51	0.58	0.06	0.01	-0.26	0.58	0.75	0.84	0.23	-0.26	0.86	-0.77	0.2	0.9	0.72	-0.66		0.84	-0.04	-0.08	-0.78	-0.17	0.78	0.73	-0.14
Non Current Assets Total	0.64	-0.59	0.7	0.09	0.05	-0.31	0.77	0.91	0.95	0.23	-0.31	0.95	-0.93	0.28	0.93	0.78	-0.77	0.84		-0.06	-0.13	-0.93	-0.25	0.9	0.91	-0.15
Non Currrent Assets Other	0.54	0.67	-0.2	0.1	0.1	-0.36	0.05	0.22	-0.05	0.71	-0.36	0.08	-0.11	0.69	-0.04	-0.07	0.51	-0.04	-0.06		0.91	-0.11	0.83	-0.14	0.2	0.38
Other Assets	0.46	0.59	-0.25	0.1	0.09	-0.28	-0.05	0.14	-0.06	0.64	-0.28	-0.01	0.03	0.67	-0.07	-0.15	0.48	-0.08	-0.13	0.91		0.02	0.8	-0.11	0.07	0.33
Retained Earnings Total Equity	-0.75	0.39	-0.59	-0.25	-0.2	0.38	-0.74	-0.95	-0.9	-0.42	0.38	-0.9	1.0	-0.47	-0.86	-0.66	0.61	-0.78	-0.93	-0.11	0.02		0.14	-0.87	-0.96	0.17
Short Term Investments	0.32	0.59	-0.04	-0.24	-0.25	-0.2	-0.12	-0.04	-0.17	0.55	-0.2	-0.11	0.15	0.4	-0.17	-0.27	0.52	-0.17	-0.25	0.83	0.8	0.14		-0.21	-0.07	0.34
Non Current Liabilities Total	0.61	-0.65	0.74	0.12	0.06	-0.26	0.67	0.83	0.98	0.26	-0.26	0.85	-0.87	0.28	0.88	0.66	-0.8	0.78	0.9	-0.14	-0.11	-0.87	-0.21		0.82	-0.19
Capital Surpluse	0.82	-0.29	0.5	0.31	0.27	-0.4	0.79	0.99	0.89	0.52	-0.4	0.91	-0.97	0.48	0.82	0.66	-0.51	0.73	0.91	0.2	0.07	-0.96	-0.07	0.82		-0.16
Inventory	-0.02	0.14	-0.01	-0.22	-0.25	-0.1	-0.11	-0.16	-0.12	0.06	-0.1	0.0	0.17	0.1	0.0	-0.14	0.15	-0.14	-0.15	0.38	0.33	0.17	0.34	-0.19	-0.16

Click cells to compare fundamentals

Puma Biotechnology Account Relationship Matchups

Puma Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	234.9M	244.2M	226.6M	222.1M	230.5M	165.1M
Total Stockholder Equity	17.5M	(6M)	(2.4M)	21.6M	53.4M	63.0M
Net Debt	60.2M	35.7M	53.5M	38.1M	26.9M	28.3M
Cash	60M	85.3M	63.1M	76.2M	84.6M	68.5M
Cash And Short Term Investments	60M	85.3M	63.1M	76.2M	95.9M	71.9M
Common Stock Shares Outstanding	38.8M	39.6M	40.6M	44.9M	47.6M	32.7M
Liabilities And Stockholders Equity	234.9M	244.2M	226.6M	222.1M	230.5M	165.1M
Other Stockholder Equity	1.3B	1.3B	1.4B	1.4B	1.4B	762.9M
Total Liab	217.4M	250.2M	229.0M	200.5M	177.1M	108.6M
Total Current Assets	166.3M	146.1M	140.0M	134.3M	156.2M	127.0M
Total Current Liabilities	90.8M	114.3M	109.6M	77.5M	99.4M	56.7M
Retained Earnings	(1.3B)	(1.3B)	(1.4B)	(1.4B)	(1.3B)	(1.3B)
Accounts Payable	19.2M	12.1M	11.2M	6.4M	6.9M	12.3M
Other Current Liab	69.0M	81.7M	91.3M	66.9M	48.9M	44.6M
Other Liab	9M	32.3M	6.4M	12.8M	14.7M	7.6M
Net Tangible Assets	(23.0M)	(80.1M)	(68.6M)	21.6M	19.4M	18.5M
Property Plant And Equipment Net	21.8M	18.9M	15.8M	12.5M	8.6M	8.4M
Non Current Assets Total	68.6M	98.1M	86.6M	87.8M	74.3M	49.8M
Non Currrent Assets Other	6.3M	5.1M	4.7M	4.7M	4.8M	5.1M
Other Assets	6.3M	5.1M	4.7M	4.7M	1.0	0.95
Long Term Debt	95.0M	84.0M	97.1M	98.3M	65.7M	54.2M
Retained Earnings Total Equity	(1.3B)	(1.3B)	(1.4B)	(1.4B)	(1.2B)	(1.3B)
Short Term Investments	51.6M	8.1M	19.0M	4.9M	11.4M	10.8M
Non Current Liabilities Total	126.6M	135.9M	119.4M	123.0M	77.7M	68.1M
Capital Surpluse	1.3B	1.3B	1.4B	1.4B	1.6B	952.6M
Inventory	3.2M	3.5M	7.1M	4.5M	7.1M	8.2M
Other Current Assets	2.7M	23.8M	18.3M	8.3M	4.7M	8.4M
Deferred Long Term Liab	5.8M	868K	955K	743K	854.5K	811.7K
Property Plant And Equipment Gross	21.8M	18.9M	22.6M	1.1M	16.3M	8.7M
Accumulated Other Comprehensive Income	(12K)	62K	0.0	(2K)	(4K)	(4.2K)
Intangible Assets	40.5M	74.1M	66.1M	70.6M	60.9M	34.3M
Property Plant Equipment	3.3M	2.5M	15.8M	1.1M	1.3M	1.3M
Net Receivables	28.9M	25.5M	32.5M	40.4M	48.5M	25.3M
Short Long Term Debt Total	120.2M	121.0M	116.6M	114.3M	111.5M	123.2M
Long Term Debt Total	151.9M	95.0M	84.0M	97.1M	111.7M	104.8M
Net Invested Capital	112.4M	92.4M	94.6M	119.9M	153.1M	135.2M
Net Working Capital	75.5M	31.9M	30.4M	56.8M	56.8M	49.8M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:

How To Invest In Puma

Details

Is Puma Stock a good investment?

Details

What is Puma Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

2.417

Earnings Share

0.47

Revenue Per Share

5.045

Quarterly Revenue Growth

0.435

Return On Assets

0.0973

The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Puma Total Revenue vs Depreciation And Amortization Analysis

Total Revenue vs Depreciation And Amortization

Total Revenue vs Depreciation And Amortization Correlation Analysis

Correlation Coefficient

Total Revenue

Depreciation And Amortization

Puma Biotechnology fundamental ratios Correlations

Puma Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Puma Biotechnology fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Retained Earnings Total Equity	+ 1.0	Retained Earnings
Capital Surpluse	+ 0.99	Other Stockholder Equity
Non Current Liabilities Total	+ 0.98	Total Liab
Cash And Short Term Investments	+ 0.97	Cash
Non Current Assets Total	+ 0.95	Total Liab

Capital Surpluse	- 0.97	Retained Earnings
Capital Surpluse	- 0.96	Retained Earnings Total Equity
Retained Earnings	- 0.96	Other Stockholder Equity
Retained Earnings Total Equity	- 0.95	Other Stockholder Equity
Retained Earnings Total Equity	- 0.93	Non Current Assets Total
Non Current Assets Total	- 0.93	Retained Earnings